{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:29:01Z","timestamp":1782217741837,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360474"],"award-info":[{"award-number":["82360474"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32271324"],"award-info":[{"award-number":["32271324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32160184"],"award-info":[{"award-number":["32160184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022957","name":"Double Thousand Plan of Jiangxi Province","doi-asserted-by":"crossref","award":["jxsq2023201116"],"award-info":[{"award-number":["jxsq2023201116"]}],"id":[{"id":"10.13039\/100022957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10540-0","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:15:45Z","timestamp":1747210545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ginkgetin inhibits the proliferation and migration of lung cancer cells via FAK\/STAT3\/AKT pathway"],"prefix":"10.1007","volume":"52","author":[{"given":"Longhua","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"3","key":"10540_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"10540_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2020.08.013","volume":"492","author":"CD Wang","year":"2020","unstructured":"Wang CD, Tan SY, Li JW, Liu WR, Peng Y, Li WM (2020) CircRNAs in lung cancer - Biogenesis, function and clinical implication. Cancer Lett 492:106\u2013115. https:\/\/doi.org\/10.1016\/j.canlet.2020.08.013","journal-title":"Cancer Lett"},{"key":"10540_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semcancer.2022.06.010","volume":"86","author":"S Srivastava","year":"2022","unstructured":"Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R (2022) Chemokines and NSCLC: emerging role in prognosis, heterogeneity, and therapeutics. Sem Cancer Biol 86:233\u2013246. https:\/\/doi.org\/10.1016\/j.semcancer.2022.06.010","journal-title":"Sem Cancer Biol"},{"issue":"11","key":"10540_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.20892\/j.issn.2095-3941.2022.0540","volume":"19","author":"T Boch","year":"2022","unstructured":"Boch T, K\u00f6hler J, Janning M, Loges S (2022) Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives. Cancer Biology Med 19(11):1543\u20131564. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0540","journal-title":"Cancer Biology Med"},{"key":"10540_CR5","doi-asserted-by":"publisher","unstructured":"Kadry YA, Lee JY, Witze ES (2021) Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis. Open Biology 11(10). https:\/\/doi.org\/10.1098\/rsob.210033","DOI":"10.1098\/rsob.210033"},{"key":"10540_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG (2022) EGFR signaling pathway as therapeutic target in human cancers. Sem Cancer Biol 85:253\u2013275. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.002","journal-title":"Sem Cancer Biol"},{"key":"10540_CR7","doi-asserted-by":"publisher","unstructured":"Wu XB, Wang J, Liang Q, Tong RS, Huang JL, Yang XW, Xu YH, Wang WJ, Sun MH, Shi JY (2022) Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment. Biomed Pharmacother 151. https:\/\/doi.org\/10.1016\/j.biopha.2022.113116","DOI":"10.1016\/j.biopha.2022.113116"},{"key":"10540_CR8","doi-asserted-by":"publisher","unstructured":"Zhou J, Yi Q, Tang LL (2019) The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review. J Experimental Clin Cancer Res 38. https:\/\/doi.org\/10.1186\/s13046-019-1265-1","DOI":"10.1186\/s13046-019-1265-1"},{"issue":"9","key":"10540_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14(9):598\u2013610. https:\/\/doi.org\/10.1038\/nrc3792","journal-title":"Nat Rev Cancer"},{"key":"10540_CR10","doi-asserted-by":"publisher","unstructured":"Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, Lappano R (2021) Focal adhesion kinase fine Tunes multifaced signals toward breast Cancer progression. Cancers 13(4). https:\/\/doi.org\/10.3390\/cancers13040645","DOI":"10.3390\/cancers13040645"},{"key":"10540_CR11","doi-asserted-by":"publisher","unstructured":"Nana FA, Vanderputten M, Ocak S (2019) Role of focal adhesion kinase in Small-Cell lung Cancer and its potential as a therapeutic target. Cancers 11(11). https:\/\/doi.org\/10.3390\/cancers11111683","DOI":"10.3390\/cancers11111683"},{"key":"10540_CR12","doi-asserted-by":"publisher","unstructured":"Pang XJ, Liu XJ, Liu Y, Liu WB, Li YR, Yu GX, Tian XY, Zhang YB, Song J, Jin CY, Zhang SY (2021) Drug discovery targeting focal adhesion kinase (FAK) as a promising Cancer therapy. Molecules 26(14). https:\/\/doi.org\/10.3390\/molecules26144250","DOI":"10.3390\/molecules26144250"},{"issue":"10","key":"10540_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/bjc.2016.331","volume":"115","author":"WB Ou","year":"2016","unstructured":"Ou WB, Lu MM, Eilers G, Li HL, Ding JY, Meng XL, Wu YH, He Q, Sheng Q, Zhou HM, Fletcher JA (2016) Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. Br J Cancer 115(10):1253\u20131263. https:\/\/doi.org\/10.1038\/bjc.2016.331","journal-title":"Br J Cancer"},{"key":"10540_CR14","doi-asserted-by":"publisher","unstructured":"Ozmadenci D, Narayanan JSS, Andrew J, Ojalill M, Barrie AM, Jiang SL, Iyer S, Chen XL, Rose M, Estrada V, Molinolo A, Bertotto T, Mikulski Z, McHale MC, White RR, Connolly DC, Pachter JA, Kuchroo VK, Stupack DG, Schlaepfer DD (2022) Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis. Proc Natl Acad Sci USA 119(17). https:\/\/doi.org\/10.1073\/pnas.2117065119","DOI":"10.1073\/pnas.2117065119"},{"issue":"19","key":"10540_CR15","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1158\/0008-5472.CAN-17-0418","volume":"77","author":"M Canel","year":"2017","unstructured":"Canel M, Byron A, Sims AH, Cartier J, Patel H, Frame MC, Brunton VG, Serrels B, Serrels A (2017) Nuclear FAK and Runx1 cooperate to regulate IGFBP3, Cell-Cycle progression, and tumor growth. Cancer Res 77(19):5301\u20135312. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0418","journal-title":"Cancer Res"},{"key":"10540_CR16","doi-asserted-by":"publisher","unstructured":"Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P, Maroyi A, Dzobo K (2018) Natural products for drug discovery in the 21st century: innovations for novel drug discovery. Int J Mol Sci 19(6). https:\/\/doi.org\/10.3390\/ijms19061578","DOI":"10.3390\/ijms19061578"},{"key":"10540_CR17","doi-asserted-by":"publisher","unstructured":"Adnan M, Rasul A, Hussain G, Shah MA, Zahoor MK, Anwar H, Sarfraz I, Riaz A, Manzoor M, Adem S, Selamoglu Z (2020) Ginkgetin: A natural biflavone with versatile Pharmacological activities. Food Chem Toxicol 145. https:\/\/doi.org\/10.1016\/j.fct.2020.111642","DOI":"10.1016\/j.fct.2020.111642"},{"key":"10540_CR18","doi-asserted-by":"publisher","unstructured":"Lou JS, Zhao LP, Huang ZH, Chen XY, Xu JT, Tai WCS, Tsim KWK, Chen YT, Xie T (2021) Ginkgetin derived from leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2\/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine 80. https:\/\/doi.org\/10.1016\/j.phymed.2020.153370","DOI":"10.1016\/j.phymed.2020.153370"},{"key":"10540_CR19","doi-asserted-by":"publisher","unstructured":"Wu LR, Qian CC, Zhang WQ, Shi MY, Chen XX, Wang Y, Lin F (2023) Ginkgetin suppresses ovarian cancer growth through Inhibition of JAK2\/STAT3 and MAPKs signaling pathways. Phytomedicine 116. https:\/\/doi.org\/10.1016\/j.phymed.2023.154846","DOI":"10.1016\/j.phymed.2023.154846"},{"issue":"4","key":"10540_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/cas.12608","volume":"106","author":"YJ Jeon","year":"2015","unstructured":"Jeon YJ, Jung SN, Yun J, Lee CW, Choi J, Lee YJ, Han DC, Kwon BM (2015) Ginkgetin inhibits the growth of DU-145 prostate cancer cells through Inhibition of signal transducer and activator of transcription 3 activity. Cancer Sci 106(4):413\u2013420. https:\/\/doi.org\/10.1111\/cas.12608","journal-title":"Cancer Sci"},{"key":"10540_CR21","doi-asserted-by":"publisher","unstructured":"Hu WH, Chan GKL, Duan R, Wang HY, Kong XP, Dong TTX, Tsim KWK (2019) Synergy of Ginkgetin and Resveratrol in suppressing VEGF-Induced angiogenesis: A therapy in treating colorectal Cancer. Cancers 11(12). https:\/\/doi.org\/10.3390\/cancers11121828","DOI":"10.3390\/cancers11121828"},{"issue":"1","key":"10540_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/15384101.2021.1995684","volume":"21","author":"Q Liu","year":"2022","unstructured":"Liu Q, Chen LY, Yin WJ, Nie YH, Zeng PH, Yang X (2022) Anti-tumor effect of Ginkgetin on human hepatocellular carcinoma cell lines by inducing cell cycle arrest and promoting cell apoptosis. Cell Cycle 21(1):74\u201385. https:\/\/doi.org\/10.1080\/15384101.2021.1995684","journal-title":"Cell Cycle"},{"key":"10540_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.biopha.2017.09.077","volume":"96","author":"J Cao","year":"2017","unstructured":"Cao J, Tong C, Liu YY, Wang JG, Ni XY, Xiong MM (2017) Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway. Biomed Pharmacother 96:450\u2013458. https:\/\/doi.org\/10.1016\/j.biopha.2017.09.077","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10540_CR24","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3892\/or.2015.4427","volume":"35","author":"M Xiong","year":"2016","unstructured":"Xiong M, Wang L, Yu HL, Han H, Mao D, Chen J, Zeng Y, He N, Liu ZG, Wang ZY, Xu SJ, Guo LY, Wang YA (2016) Ginkgetin exerts growth inhibitory and apoptotic effects on osteosarcoma cells through Inhibition of STAT3 and activation of caspase-3\/9. Oncol Rep 35(2):1034\u20131040. https:\/\/doi.org\/10.3892\/or.2015.4427","journal-title":"Oncol Rep"},{"key":"10540_CR25","doi-asserted-by":"publisher","unstructured":"Liu KL, Fu XJ, Wang ZQ, Yang L, Yang J, Deng HB (2023) Integrating network Pharmacology prediction and experimental investigation to verify Ginkgetin anti-invasion and metastasis of human lung adenocarcinoma cells via the Akt\/GSK-3\u03b2\/Snail and Wnt\/\u03b2-catenin pathway. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1135601","DOI":"10.3389\/fphar.2023.1135601"},{"key":"10540_CR26","doi-asserted-by":"publisher","unstructured":"Zou SL, Tong QY, Liu BW, Huang W, Tian Y, Fu XH (2020) Targeting STAT3 in Cancer immunotherapy. Mol Cancer 19(1). https:\/\/doi.org\/10.1186\/s12943-020-01258-7","DOI":"10.1186\/s12943-020-01258-7"},{"issue":"24","key":"10540_CR27","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/0008-5472.Can-24-1846","volume":"84","author":"E Sementino","year":"2024","unstructured":"Sementino E, Hassan D, Bellacosa A, Testa JR (2024) AKT and the hallmarks of Cancer. Cancer Res 84(24):4126\u20134139. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-1846","journal-title":"Cancer Res"},{"key":"10540_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.canlet.2019.10.030","volume":"469","author":"M Wu","year":"2020","unstructured":"Wu M, Zhang PH (2020) EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett 469:207\u2013216. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.030","journal-title":"Cancer Lett"},{"issue":"3","key":"10540_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1039\/d1np00026h","volume":"39","author":"XG Liu","year":"2022","unstructured":"Liu XG, Lu X, Gao W, Li P, Yang H (2022) Structure, synthesis, biosynthesis, and activity of the characteristic compounds from L. Nat Prod Rep 39(3):474\u2013511. https:\/\/doi.org\/10.1039\/d1np00026h","journal-title":"Nat Prod Rep"},{"key":"10540_CR30","doi-asserted-by":"publisher","unstructured":"Samec D, Karalija E, Dahija S, Hassan STS (2022) Biflavonoids: important contributions to the health benefits of Ginkgo (L). Plants-Basel 11(10). https:\/\/doi.org\/10.3390\/plants11101381","DOI":"10.3390\/plants11101381"},{"key":"10540_CR31","doi-asserted-by":"publisher","unstructured":"Spallarossa A, Tasso B, Russo E, Villa C, Brullo C (2022) The development of FAK inhibitors: A Five-Year update. Int J Mol Sci 23(12). https:\/\/doi.org\/10.3390\/ijms23126381","DOI":"10.3390\/ijms23126381"},{"issue":"2","key":"10540_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13543776.2018.1414183","volume":"28","author":"PC Lv","year":"2018","unstructured":"Lv PC, Jiang AQ, Zhang WM, Zhu HL (2018) FAK inhibitors in cancer, a patent review. Expert Opin Ther Pat 28(2):139\u2013145. https:\/\/doi.org\/10.1080\/13543776.2018.1414183","journal-title":"Expert Opin Ther Pat"},{"issue":"23","key":"10540_CR33","doi-asserted-by":"publisher","first-page":"14382","DOI":"10.1021\/acs.jmedchem.0c01248","volume":"63","author":"Y Lu","year":"2020","unstructured":"Lu Y, Sun HY (2020) Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK). J Med Chem 63(23):14382\u201314403. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01248","journal-title":"J Med Chem"},{"issue":"5","key":"10540_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18(5):516\u2013523. https:\/\/doi.org\/10.1016\/j.ceb.2006.08.011","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"10540_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10456-021-09802-9","volume":"24","author":"DM Lees","year":"2021","unstructured":"Lees DM, Reynolds LE, Pedrosa AR, Roy-Luzarraga M, Hodivala-Dilke KM (2021) Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression (Mar, 10.1007\/s10456-021-09776-8, 2021). Angiogenesis 24(3):483\u2013487. https:\/\/doi.org\/10.1007\/s10456-021-09802-9","journal-title":"Angiogenesis"},{"issue":"2","key":"10540_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"H Yoon","year":"2015","unstructured":"Yoon H, Dehart JP, Murphy JM, Lim STS (2015) Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochemistry 63(2):114\u2013128. https:\/\/doi.org\/10.1369\/0022155414561498","journal-title":"J Histochem Cytochemistry"},{"key":"10540_CR37","doi-asserted-by":"publisher","unstructured":"Wang WY, McDonald MCL, Kim C, Ma MRL, Pan Z, Kaufmann C, Frank DA (2023) The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1265818","DOI":"10.3389\/fimmu.2023.1265818"},{"issue":"13","key":"10540_CR38","doi-asserted-by":"publisher","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","volume":"64","author":"JY Dong","year":"2021","unstructured":"Dong JY, Cheng XD, Zhang WD, Qin JJ (2021) Recent update on development of Small-Molecule STAT3 inhibitors for Cancer therapy: from phosphorylation Inhibition to protein degradation. J Med Chem 64(13):8884\u20138915. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00629","journal-title":"J Med Chem"},{"key":"10540_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi S, Munirajan AK (2019) Akt in cancer: mediator and more. Sem Cancer Biol 59:80\u201391. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.002","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"10540_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","volume":"24","author":"A Tomas","year":"2014","unstructured":"Tomas A, Futter CE, Eden ER (2014) EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 24(1):26\u201334. https:\/\/doi.org\/10.1016\/j.tcb.2013.11.002","journal-title":"Trends Cell Biol"},{"key":"10540_CR41","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3\u2013S8. https:\/\/doi.org\/10.1016\/s0959-8049(01)00230-1","journal-title":"Eur J Cancer"},{"issue":"1","key":"10540_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tcb.2021.07.001","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu J, Peng YH, Wei WY (2022) Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol 32(1):30\u201344. https:\/\/doi.org\/10.1016\/j.tcb.2021.07.001","journal-title":"Trends Cell Biol"},{"key":"10540_CR43","doi-asserted-by":"publisher","unstructured":"Shi J, Ye GQ, Zhao GL, Wang XD, Ye CH, Thammavong K, Xu J, Dong JH (2018) Coordinative control of G2\/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma. Peerj 6. https:\/\/doi.org\/10.7717\/peerj.5787","DOI":"10.7717\/peerj.5787"},{"issue":"3","key":"10540_CR44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.gendis.2020.01.001","volume":"8","author":"XG Ma","year":"2021","unstructured":"Ma XG, Xiang F, Pei Z, Miao JF, Wu P, Song XF, Li YH, Zhang YM (2021) Circ-Smad5 retards the G1\/S transition of cell cycle via inhibiting the activity of wnt\/lef\/cyclind1 signaling in JB6 cells. Genes Dis 8(3):364\u2013372. https:\/\/doi.org\/10.1016\/j.gendis.2020.01.001","journal-title":"Genes Dis"},{"issue":"14","key":"10540_CR45","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/0008-5472.Can-13-3440","volume":"74","author":"L Gopinathan","year":"2014","unstructured":"Gopinathan L, Tan SLW, Padmakumar VC, Coppola V, Tessarollo L, Kaldis P (2014) Loss of Cdk2 and CyclinA2 impairs cell proliferation and tumorigenesis. Cancer Res 74(14):3870\u20133879. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-3440","journal-title":"Cancer Res"},{"key":"10540_CR46","doi-asserted-by":"publisher","unstructured":"He CP, Chen YT, Zhang XM, Feng HC, Rao YZ, Ji TY, Wang WY (2024) Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1. Sci Rep 14(1). https:\/\/doi.org\/10.1038\/s41598-024-77980-9","DOI":"10.1038\/s41598-024-77980-9"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10540-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:30:39Z","timestamp":1766853039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10540-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10540"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10540-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"458"}}